APA (7th ed.) Citation

J, G., JC, N., M, J., J, F., F, F., C, M., . . . C, A. (2024). IKZF1plus is a frequent biomarker of adverse prognosis in Mexican pediatric patients with B-acute lymphoblastic leukemia. Frontiers in oncology, 14, 1337954. https://doi.org/10.3389/fonc.2024.1337954

Chicago Style (17th ed.) Citation

J, Garcia-Solorio, et al. "IKZF1plus Is a Frequent Biomarker of Adverse Prognosis in Mexican Pediatric Patients with B-acute Lymphoblastic Leukemia." Frontiers in Oncology 14 (2024): 1337954. https://doi.org/10.3389/fonc.2024.1337954.

MLA (9th ed.) Citation

J, Garcia-Solorio, et al. "IKZF1plus Is a Frequent Biomarker of Adverse Prognosis in Mexican Pediatric Patients with B-acute Lymphoblastic Leukemia." Frontiers in Oncology, vol. 14, 2024, p. 1337954, https://doi.org/10.3389/fonc.2024.1337954.